Wood-decaying fungi found in Ghana: A rich source of new anti-infective compounds.
Samuel Yaw AboagyeVincent AmarhPaul A LarteyPatrick Kobina ArthurPublished in: AAS open research (2019)
Background: Discovery of bioactive natural products are instrumental for development of novel antibiotics. The discovery and development of natural products such as penicillin represented a major milestone in the treatment of bacterial infections. Currently, many antibiotics have lost their relevance in clinics due to the emergence of drug-resistant microbial pathogens. Hence, there is the need for continuous search of new compounds endowed with potent antimicrobial activity. Methods: In this study, wood-decaying fungi (WDF) from Ghana were explored for their potential as sources of novel antimicrobial compounds with intent of expanding the effort into a drug discovery programme in the near future. Extracts from cultures of 54 morphologically distinct WDF isolates were analyzed for the presence of antimicrobial agents. Results: The extracts from 40 out of the 54 WDF isolates exhibited significant antimicrobial activity against either Staphylococcus aureus , Escherichia coli or Candida albicans. Fractionation of these bioactive extracts, followed by bioassay of the organic fractions obtained, indicate that extracts exhibiting antimicrobial activity against more than one of the three test organisms could be attributed to the presence of different bioactive compounds. Analysis of the composition of the extracts revealed that terpenes were predominant. Conclusions: This study suggests that a significant proportion of WDF in Ghana produce antimicrobial compounds which could be potential sources of novel anti-infective agents and support the plans of developing a drug discovery programme in Ghana based on the fermentation of WDF.
Keyphrases
- drug discovery
- staphylococcus aureus
- drug resistant
- candida albicans
- biofilm formation
- escherichia coli
- multidrug resistant
- small molecule
- high throughput
- acinetobacter baumannii
- gram negative
- randomized controlled trial
- clinical trial
- single cell
- pseudomonas aeruginosa
- climate change
- current status
- klebsiella pneumoniae
- risk assessment
- cystic fibrosis